FDA warns Meridian Bioscience's Magellan Diagnostics over quality system failures and unreported problems with its blood lead test kits.
What happened
FDA inspected Magellan Diagnostics, Inc. in North Billerica, MA from August 5 to August 26, 2025, and found the firm's quality system for its blood lead testing devices did not meet the Quality System regulation. FDA also found the firm did not open corrective actions for about 179 false positive complaints and missed the required 30-day report for a false negative result tied to a corroded sensor pin. The firm's written responses were largely judged not adequate.
What FDA found
The firm did not follow its own corrective and preventive action procedure, failing to open actions when false positive and out-of-range control complaints rose.
21 CFR 820.100(a)The firm never set written design requirements for the Level 1 and Level 2 controls used with the LeadCare II system.
21 CFR 820.30(c)The firm did not validate the cleaning and decontamination steps in its instructions for use, and did not update its risk files after new hazards such as false positives and mislabeled product appeared.
21 CFR 820.30(g)The firm changed critical manufacturing acceptance criteria without validating the revised process, and its calibration verification procedure lets operators leave out high results and outliers.
21 CFR 820.75(a)Incoming inspection of the capillary collection tubes checked only packaging and no critical quality attributes.
21 CFR 820.80(b)The firm did not report a device malfunction to FDA within 30 days, including a false negative pediatric result caused by a corroded sensor pin.
21 CFR 803.50(a)(2)
What FDA wants
FDA asks the firm to write back within 15 business days with the steps taken, documentation of fixes that address root causes, and a timetable for anything still open. FDA also requires certification from an outside expert who audits the firm's manufacturing and quality systems, due July 31, 2026, with follow-up certifications in 2027 and 2028.
Who should pay attention
- labs and clinics that run blood lead tests on these analyzers
- distributors and brands that sell LeadCare products
- diagnostics makers that handle complaints and device malfunction reporting
This is a summary. Read the original letter on fda.gov.